CRMD
CorMedix Inc
7.80$
+0.6%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.8% | 99.9% | 99.7% | 98.6% | 99.1% | 99.6% | 97.7% | 96.4% | 96.0% | 96.8% | 96.4% | 44.4% | |
| 85.1% | 31.9% | 36.8% | 77.2% | 93.6% | 56.1% | 85.0% | 77.3% | 69.9% | 53.2% | 34.2% | 17.7% | |
| 85.1% | 95.4% | 92.1% | 89.1% | 93.6% | 96.7% | 94.0% | 95.0% | 95.1% | 92.7% | 43.5% | 18.1% | |
| 1.6% | 0.9% | 0.1% | 0.5% | 0.1% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 43.5% | 20.7% | |
| 9.1% | 1.0% | 0.8% | 4.4% | 2.3% | 1.1% | 0.3% | 0.0% | 0.0% | 2.6% | 6.4% | 3.6% | |
| 0.8% | 0.1% | 0.3% | 1.4% | 0.9% | 0.4% | 2.3% | 2.1% | 3.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | 1,550.2% | 3.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | 1.6% | 45.9% | |
| 28.7% | 8.3% | 18.7% | 46.5% | 73.8% | 19.8% | 10.3% | 8.9% | 11.2% | 14.5% | 28.8% | 50.9% | |
| 28.0% | 8.3% | 18.7% | 46.5% | 41.3% | 19.8% | 8.4% | 7.8% | 10.2% | 13.9% | 28.5% | 21.1% | |
| – | 0.2% | 0.0% | – | – | 0.0% | 0.2% | 0.2% | 0.2% | 0.2% | 0.1% | 0.2% | |
| 17.5% | 4.6% | 7.5% | 13.4% | 13.8% | 3.5% | 2.3% | 3.2% | 3.5% | 5.2% | 1.4% | 1.0% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 32.5% | – | – | – | – | – | – | 17.5% | |
| 71.3% | 91.7% | 81.3% | -1,131.1% | -950.8% | -663.0% | 89.7% | 91.1% | 88.8% | 85.5% | 71.2% | 49.1% | |
| -1,494.9% | -254.4% | -544.0% | -1,131.1% | -950.8% | -663.0% | -441.0% | -356.3% | -443.9% | -392.0% | -285.8% | -21.4% | |
| 84.1% | 16.9% | 34.7% | 82.0% | 94.6% | 81.9% | 57.9% | 54.6% | 64.9% | 62.0% | 49.5% | 9.7% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.